Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.